Press
-
Topos Bio Introduces Topos-2 and Topos-Bind to Combat “Undruggable” Diseases
Early testing showed that Topos-2 was nearly 4x closer to experimental ground-truth than the next-best model, and Topos-Bind was the only model able to predict how the shape of amyloid-beta, an Alzheimer's target, changes with drugs
Read Press Release → -
Topos Bio Secures $10.5M to Tackle 'Undruggable' Proteins Driving Alzheimer's and Cancer
Founded by Berkeley and Stanford researchers, Topos unveils breakthrough foundation model for disordered proteins and partnering with Gladstone Institutes.
Read Press Release →